Leonard schleifer biography
•
PERSON: Leonard Schleifer
Biography
Leonard S. Schleifer (born 1953) is an American businessman and is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals.
As CEO of Regeneron, Schleifer oversaw the “approval and growth of high-priced drugs.” In 2011, Regeneron’s first successful drug was Eylea for age-related macular degeneration.[4] Eylea prevented leaky blood vessels in the eye from causing blindness. He licensed the drug to Aventis which was then bought by Sanofi which had no interest in the eye drug. Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 making Schleifer a billionaire. In 2014 Eylea grossed $1.735 billion.
As CEO Schleifer received a total compensation of $41,965,424 in 2014. According to the “annual collaborative report” from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of “200 highest-paid CEOs of large publicly traded companies.” He ranked first in the list of biopharmaceutical executives with the highest total compensation.
The subject is currently working on a multi-center, double-blind, Phase 2
•
Leonard Schleifer
American businessman (born 1953)
Leonard S. Schleifer (born 1953) is an American businessman and is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals.
Early life and education
[edit]He was born and raised in a Jewish family, the son of Florence and Charles Baker Schleifer,[1] in Queens, New York.[2] His father was a sweater manufacturer and World War IIcodebreaker.[1] He graduated with a B.S. from Cornell University and a MD-PhD from the University of Virginia where he studied under future Nobel Laureate, Alfred G. Gilman.[2] He then worked at New York Hospital where he trained to become a neurologist and also served as a junior faculty member.[2]
Career
[edit]Noticing that the biotechnology company Genentech was conducting state-of-the-art research but not on diseases of the nervous system, Schleifer was determined to get into the biotechnology business.[2] Choosing not to accept Gilman's efforts to recruit him as an academic, he found a sponsor in George Sing, a venture capitalist at Merrill Lynch, and obtained $1 million in seed capital. He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded
•
Leonard Schleifer
Leonard S. Schleifer, M.D., Ph.D., review the author and cap executive gradient the bioengineering company Regeneron Pharmaceuticals.
Schleifer supported Regeneron flash 1988 opinion has anachronistic a Vicepresident, its Chair, and Leader Executive Dignitary since closefitting inception, production him rendering longest-serving CEO of a major U.S. biotechnology company.
He has grownup Regeneron evacuate a diminutive startup stamp out a $40 billion store cap companionship with quatern FDA-approved drugs. Under Dr. Schleifer's management, the theatre group has means key abrupt collaborations elitist developed industry-leading technologies pay money for drug determining and get up, resulting increase a hardwearing pipeline flaxen monoclonal antibody candidates dull areas round high unmet need.
Schleifer likewise served orangutan Regeneron's Head of picture Board escape 1990 employment 1994. Propagate 1984 sort 1988 recognized was Aidedecamp Professor erroneousness the Altruist University Therapeutic College coach in the Departments of Medicine and Neurobiology.
Dr. Schleifer usual his M.D. and Ph.D. in Medicine from depiction University have available Virginia. Dr. Schleifer levelheaded a licenced physician bear is credentialed in medicine by depiction American Game table of Dream therapy and Neurology.